In Q3 of 2014, the national drug market size of hospitals above the second level (based on retail price) was 246.8 billion yuan, up 22.2% year on year. For details of category, manufacturer and single product ranking, see the text.
Overall market performance
According to the data of Zhongkang CMH, in Q3 of 2014, the drug market size of hospitals above the second level nationwide (based on the retail price) was 246.8 billion yuan, with a year-on-year increase of 22.2% - the highest year-on-year growth rate in the first three quarters of 2014. However, in fact, Q3 was only 1.5% higher than Q2, so the high quarterly growth rate was more due to the small market size of Q3 in 2013 than the signal of market recovery. In fact, compared with the first three quarters of 2013, the market size in the first three quarters of 2014 increased by 17.4% year-on-year.
In Q3 2014, the market size of chemical drugs was 197.3 billion yuan, and that of Chinese patent drugs was 47 billion yuan. The proportion of Chinese patent drugs has risen to the highest level since 2013, accounting for 19.1%. In the first three quarters of 2014 as a whole, the growth rate of the market size of Chinese patent medicine was higher than that of chemical medicine, with the former increasing by 21.9% year-on-year and the latter by 16.4% year-on-year.
From the perspective of channels, the growth rate of city-level hospitals in the first three quarters of 2014 was slightly higher than that of county-level hospitals, with year-on-year growth of 17.5% and 16.9% respectively. In Q3 of 2014, city-level hospitals accounted for 76.7% of the drug market of hospitals at or above the national level. In Q3 of 2014, the sales volume was 189.2 billion yuan, while county-level hospitals only accounted for 23.3% of the market share, with sales volume of 57.6 billion yuan.
The drug market size of tertiary and secondary hospitals is basically consistent with Q1 and Q2. In Q3 of 2014, the drug market size of tertiary hospitals nationwide was 143.4 billion yuan, while the drug market size of secondary hospitals was 103.4 billion yuan. The proportion of Class III hospitals in the drug market of hospitals above Class II in the country is slightly lower than the overall level of the first three quarters, 58.1% (58.2% in the first three quarters), but the market scale of Class III hospitals in the first three quarters of 2014 grew faster, with a year-on-year growth of 19.3%, 4.5 percentage points higher than that of Class II hospitals.
Prescription drugs continue to occupy an absolute advantage in the hospital market. In Q3 of 2014, prescription drugs in hospitals at or above the national level accounted for 94.2%, with a market scale of 232.5 billion yuan.
Performance of multinational and local enterprises
In Q3 of 2014, the top 10 enterprises with the highest sales volume in the drug market of hospitals above the second level in the country continued to keep consistent with Q1 and Q2, but the ranking of four enterprises changed.
The most significant change is that the local enterprise Yangzijiang Pharmaceutical Co., Ltd. has taken the championship position, with the market scale of 5.1 billion yuan, up 10.3% month-on-month - this is that Yangzijiang has increased by more than 10% month-on-month for two consecutive quarters. In the first three quarters of 2014, the growth rate of Yangtze River was the fastest among the top 10 enterprises, with a year-on-year increase of 28.2%.
The multinational pharmaceutical company Pfizer became the runner-up, with a market size of 5 billion yuan, up 25.8% year on year in the first three quarters. AstraZeneca followed closely, with a market size of 4.9 billion yuan, up 22.8% year on year in the first three quarters.
In addition, Sanofi Q3 grew by 15.9% month-on-month, which is the fastest growth of the top 10 enterprises in the central ring. The market size reached 4.1 billion yuan, surpassing Bayer Healthcare and returning to the fourth place.
Category and single product
Under the influence of anti-infective restriction orders, systemic anti-infective drugs continued to grow at a low rate. By Q3 2014, they had been surpassed by cardiovascular system drugs and were no longer the largest category. The cardiovascular system drugs have become the largest category with a year-on-year growth rate of 17.1% in the first three quarters, and the market size of Q3 in 2014 reached 42.6 billion yuan.
However, the fastest growing category is anti-tumor and immunomodulators, with a year-on-year increase of 35.9% in the first three quarters. The market size of Q3 in 2014 has reached 31.4 billion yuan.
In terms of single products, the market pattern has also changed significantly. Among them, the champion single product Xueshuantong in the first two quarters showed negative growth, down 5.3% year-on-year and 12.5% month-on-month.
In addition, Shuanglu-compound coenzyme was the single product with the highest year-on-year growth in the first three quarters of 2014, reaching 41.5%. In 2014, the market size of Q3 was 1.4 billion yuan, making it the second largest single product in the drug market sales of hospitals at and above the national level. Another single product with rapid growth is Xiyanping, with a year-on-year growth of 41.1% in the first three quarters of 2014, but a year-on-year growth of only 3.0% in Q3 in 2014. Therefore, compared with Q2, its ranking has dropped by one place.
While Beqing Star has slightly decreased in Q3, its year-on-year growth in the first three quarters is still 28.2%, and its month-on-month decline may be seasonal.
